These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28987595)

  • 1. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties.
    O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
    Biochem Pharmacol; 2017 Dec; 146():165-173. PubMed ID: 28987595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
    O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
    Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice.
    O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
    PLoS One; 2018; 13(8):e0202350. PubMed ID: 30157220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db mice.
    O'Harte FPM; Parthsarathy V; Flatt PR
    Mol Cell Endocrinol; 2020 Mar; 504():110695. PubMed ID: 31904406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation.
    Tanday N; Irwin N; Moffett RC; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2020 Dec; 22(12):2468-2478. PubMed ID: 32844576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
    Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
    Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esculentin-2CHa(1-30) and its analogues: stability and mechanisms of insulinotropic action.
    Vasu S; McGahon MK; Moffett RC; Curtis TM; Conlon JM; Abdel-Wahab YH; Flatt PR
    J Endocrinol; 2017 Mar; 232(3):423-435. PubMed ID: 28115493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
    Martin CM; Irwin N; Flatt PR; Gault VA
    Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
    Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
    Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
    Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
    Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lipoic acid on apelin in 3T3-L1 adipocytes and in high-fat fed rats.
    Fernández-Galilea M; Pérez-Matute P; Prieto-Hontoria P; Martínez JA; Moreno-Aliaga MJ
    J Physiol Biochem; 2011 Sep; 67(3):479-86. PubMed ID: 21461750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Islet APJ Deletion Reduces Islet Density and Glucose Tolerance in Mice.
    Han S; Englander EW; Gomez GA; Rastellini C; Quertermous T; Kundu RK; Greeley GH
    Endocrinology; 2015 Jul; 156(7):2451-60. PubMed ID: 25965959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
    Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
    Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice.
    Sörhede Winzell M; Magnusson C; Ahrén B
    Regul Pept; 2005 Nov; 131(1-3):12-7. PubMed ID: 15970338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone induces apelin mRNA expression and secretion in mouse 3T3-L1 adipocytes.
    Kralisch S; Lossner U; Bluher M; Paschke R; Stumvoll M; Fasshauer M
    Regul Pept; 2007 Mar; 139(1-3):84-9. PubMed ID: 17126924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brevinin-2-related peptide and its [D4K] analogue stimulate insulin release in vitro and improve glucose tolerance in mice fed a high fat diet.
    Abdel-Wahab YH; Patterson S; Flatt PR; Conlon JM
    Horm Metab Res; 2010 Aug; 42(9):652-6. PubMed ID: 20496306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N; Montgomery IA; Moffett RC; Flatt PR
    Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.